交易 Monopar Therapeutics Inc. - MNPR CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
| 价差 | - | ||||||||
|
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
|
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
| 隔夜费时间 | 21:00 (UTC) | ||||||||
| 最小交易量 | 1 | ||||||||
| 货币 | USD | ||||||||
| 保证金 | 20% | ||||||||
| 上市交易所 | United States of America | ||||||||
| 交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
|---|
Monopar Therapeutics Inc. Events
| 時間（協調世界時） (UTC) | 國家 | 事件 |
|---|---|---|
| No events scheduled | ||
- 年度
- 每季度
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 | 0 |
| 收入 | 0 | 0 | 0 | 0 | ||
| 总营业费用 | 1.19283 | 16.6031 | 3.33115 | 4.32376 | 6.50888 | 9.12725 |
| 销售/一般/行政费用，总计 | 0.91247 | 1.16619 | 1.55669 | 2.35524 | 2.44368 | 2.63404 |
| 研究与开发 | 0.28036 | 15.4369 | 1.77445 | 1.96852 | 4.0652 | 6.49321 |
| 营业收入 | -1.19283 | -16.6031 | -3.33115 | -4.32376 | -6.50888 | -9.12725 |
| 利息收入（费用），非经营净值 | 0.00723 | 0.04826 | 0.10322 | 0.09889 | 0.0819 | 0.02402 |
| 税前净收入 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 税后净收入 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 未计算非常项目前的净收益 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 净收入 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 普通股股东可获收益 (不含非经常性项目) | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 普通股股东可获收益 (含非經常性項目) | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 摊薄净收入 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 摊薄后加权平均股 | 10.421 | 10.421 | 10.421 | 10.421 | 10.9583 | 12.4722 |
| 扣除特别项目的每股摊薄盈利 | -0.11377 | -1.58861 | -0.30975 | -0.40542 | -0.57533 | -0.72988 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |||
| 每股正常摊薄盈利 | -0.11377 | -1.58861 | -0.30975 | -0.40542 | -0.57533 | -0.72988 |
| 其他，净值 | 0.1224 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 |
| 总营业费用 | 1.89472 | 2.0924 | 2.45902 | 2.68112 | 2.45719 |
| 销售/一般/行政费用，总计 | 0.68794 | 0.61597 | 0.6317 | 0.69844 | 0.77925 |
| 研究与开发 | 1.20678 | 1.47643 | 1.82732 | 1.98268 | 1.67793 |
| 营业收入 | -1.89472 | -2.0924 | -2.45902 | -2.68112 | -2.45719 |
| 利息收入（费用），非经营净值 | 0.0107 | 0.01223 | 0.00058 | 0.00053 | 0.00046 |
| 税前净收入 | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 税后净收入 | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 未计算非常项目前的净收益 | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 净收入 | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 普通股股东可获收益 (不含非经常性项目) | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 普通股股东可获收益 (含非經常性項目) | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 摊薄净收入 | -1.88402 | -2.08017 | -2.45844 | -2.68059 | -2.45672 |
| 摊薄后加权平均股 | 12.1394 | 12.5699 | 12.5827 | 12.5919 | 12.6044 |
| 扣除特别项目的每股摊薄盈利 | -0.1552 | -0.16549 | -0.19538 | -0.21288 | -0.19491 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| 每股正常摊薄盈利 | -0.1552 | -0.16549 | -0.19538 | -0.21288 | -0.19491 |
- 年度
- 每季度
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| 流动资产总额 | 2.09517 | 9.13124 | 7.25222 | 13.2296 | 16.7998 | 20.5216 |
| 现金和短期投资 | 2.07261 | 8.98189 | 6.89277 | 13.2139 | 16.7371 | 20.3039 |
| 现金等价物 | 2.07261 | 8.98189 | 6.89277 | 13.2139 | 16.7371 | 20.3039 |
| Other Current Assets, Total | 0.02256 | 0.14934 | 0.35945 | 0.01571 | 0.06269 | 0.21775 |
| Total Assets | 2.89557 | 9.93127 | 7.31796 | 13.352 | 16.8687 | 20.5216 |
| Other Long Term Assets, Total | 0.80039 | 0.80003 | 0.06573 | 0.12238 | 0.06886 | 0 |
| Total Current Liabilities | 0.06451 | 0.31187 | 0.39955 | 0.72417 | 1.17667 | 1.58054 |
| Payable/Accrued | 0.06451 | 0.31187 | 0.39955 | 0.72417 | 1.17667 | 1.58054 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.06451 | 0.31187 | 0.39955 | 0.72417 | 1.17667 | 1.58054 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 2.83106 | 9.6194 | 6.9184 | 12.6279 | 15.692 | 18.9411 |
| Preferred Stock - Non Redeemable, Net | 0.00012 | |||||
| Common Stock | 0 | 0.00929 | 0.00929 | 0.01059 | 0.01145 | 0.0126 |
| Additional Paid-In Capital | 4.70385 | 28.0379 | 28.5672 | 38.5088 | 47.8736 | 60.22 |
| Other Equity, Total | -1.87291 | -18.4278 | -0.0024 | -0.01097 | -0.00787 | -0.00316 |
| Total Liabilities & Shareholders’ Equity | 2.89557 | 9.93127 | 7.31796 | 13.352 | 16.8687 | 20.5216 |
| Total Common Shares Outstanding | 10.421 | 10.421 | 10.421 | 10.6215 | 11.4535 | 12.5981 |
| Retained Earnings (Accumulated Deficit) | -21.6557 | -25.8806 | -32.1852 | -41.2884 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| 流动资产总额 | 25.8377 | 24.3884 | 22.4484 | 20.5216 | 18.0127 |
| 现金和短期投资 | 25.7231 | 24.2929 | 22.3416 | 20.3039 | 17.819 |
| 现金等价物 | 25.7231 | 24.2929 | 22.3416 | 20.3039 | 17.819 |
| Other Current Assets, Total | 0.11457 | 0.09556 | 0.1068 | 0.21775 | 0.19364 |
| Total Assets | 25.9065 | 24.4573 | 22.5172 | 20.5216 | 18.0664 |
| Other Long Term Assets, Total | 0.06886 | 0.06886 | 0.06886 | 0 | |
| Total Current Liabilities | 0.80627 | 1.10364 | 1.23994 | 1.58054 | 1.07412 |
| Payable/Accrued | 0.80627 | 1.10364 | 1.23994 | 1.58054 | 1.04815 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.80627 | 1.10364 | 1.23994 | 1.58054 | 1.09946 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 25.1003 | 23.3536 | 21.2773 | 18.9411 | 16.9669 |
| Common Stock | 0.01257 | 0.01258 | 0.01259 | 0.0126 | 0.01262 |
| Additional Paid-In Capital | 59.162 | 59.4955 | 59.8776 | 60.22 | 60.7031 |
| Retained Earnings (Accumulated Deficit) | -34.0692 | -36.1493 | -38.6078 | -41.2884 | -43.7451 |
| Other Equity, Total | -0.0051 | -0.00516 | -0.00515 | -0.00316 | -0.00374 |
| Total Liabilities & Shareholders’ Equity | 25.9065 | 24.4573 | 22.5172 | 20.5216 | 18.0664 |
| Total Common Shares Outstanding | 12.5699 | 12.5827 | 12.5906 | 12.5981 | 12.6206 |
| Property/Plant/Equipment, Total - Net | 0.05369 | ||||
| Accrued Expenses | 0.02598 | ||||
| Other Liabilities, Total | 0.02534 |
- 年度
- 每季度
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| 净收入/起跑线 | -1.1856 | -16.5549 | -3.22793 | -4.22487 | -6.30457 | -9.10322 |
| 经营活动产生的现金 | -1.19463 | -2.62747 | -2.68049 | -3.01768 | -4.66227 | -7.3174 |
| 非现金物品 | 0 | 13.8068 | 0.52933 | 1.01117 | 1.19849 | 1.46805 |
| 营运资金的变化 | -0.00904 | 0.12058 | 0.01811 | 0.19602 | 0.44381 | 0.31777 |
| 融资活动产生的现金 | 1.2625 | 9.53639 | -0.20627 | 9.34741 | 8.18212 | 10.8795 |
| 融资现金流项目 | 0 | 4.83074 | -0.20627 | -0.98481 | -0.11557 | -0.06325 |
| 股票的发行（报废），净额 | 1.2625 | 4.70565 | 0 | 10.3322 | 8.17529 | 10.9428 |
| 现金净变化 | 0.06787 | 6.90892 | -2.88915 | 6.32116 | 3.52318 | 3.56676 |
| 外汇效应 | -0.0024 | -0.00857 | 0.00333 | 0.00462 | ||
| Cash Taxes Paid | -0.0111 | 0 | ||||
| 债务的发行（退还），净额 | 0.1224 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -1.88402 | -3.96419 | -6.42263 | -9.10322 | -2.45672 |
| Cash From Operating Activities | -1.93806 | -3.34418 | -5.2855 | -7.3174 | -2.4675 |
| Non-Cash Items | 0.36823 | 0.72583 | 1.11789 | 1.46805 | 0.49981 |
| Changes in Working Capital | -0.42227 | -0.10582 | 0.01925 | 0.31777 | -0.51059 |
| Cash From Financing Activities | 10.9213 | 10.8973 | 10.8873 | 10.8795 | -0.01667 |
| Financing Cash Flow Items | -0.0215 | -0.0455 | -0.05548 | -0.06325 | -0.01667 |
| Issuance (Retirement) of Stock, Net | 10.9428 | 10.9428 | 10.9428 | 10.9428 | 0 |
| Foreign Exchange Effects | 0.00277 | 0.00263 | 0.00264 | 0.00462 | -0.00066 |
| Net Change in Cash | 8.986 | 7.55574 | 5.60446 | 3.56676 | -2.48483 |
| Issuance (Retirement) of Debt, Net | 0 | 0 |
为什么选择 Capital.com？让我们的数字来说话。
Capital.com Group交易計算器
如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模（槓桿 x 投資）：
開倉
平倉
做空 做多
Monopar Therapeutics Inc. Company profile
关于 Monopar Therapeutics Inc.
Monopar Therapeutics Inc.是一家处于临床阶段的生物制药公司。 该公司主要致力于开发为癌症患者设计的治疗药物。 其产品管线包括Validive、camsirubicin、MNPR-101和MNPR-202。 Validive是第一种用于预防口咽癌患者辐射诱发的严重口腔粘膜炎（SOM）的粘性口腔片。 它的camsirubicin是一种处于临床阶段的拓扑异构酶II-α选择性的多柔比星的新型类似物，专门用于保留抗癌活性，同时最大限度地减少对心脏的毒性影响。 其MNPR-101是一种人源化单克隆抗体，旨在结合癌细胞上发现的特定细胞表面受体--尿激酶浆细胞激活剂受体（uPAR），并阻断肿瘤生长和进展所需的若干途径。 MNPR-202是一种用于各种癌症的早期坎柔比星类似物。
| Industry: | Biotechnology & Medical Research (NEC) |
1000 Skokie Blvd Ste 350
WILMETTE
ILLINOIS 60091-1146
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗？
加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。